USD
BPC-157 vs TB-500 is not a comparison between two versions of the same peptide. BPC-157 is described as a 15-amino-acid peptide, while thymosin beta-4 is a 43-amino-acid endogenous peptide. TB-500 naming may refer to thymosin-beta-4-related material, so exact identity matters before any evidence is compared.
- Compare identity and sequence before comparing claimed purpose.
- Separate evidence for thymosin beta-4 from evidence for a TB-500-labeled product.
- Treat blend mass and component mass as different fields.
BPC-157 vs TB-500 at a glance
| Comparison field | BPC-157 | TB-500 / thymosin-beta-4-related |
|---|---|---|
| Molecular description | 15-amino-acid peptide | Catalog terminology related to thymosin beta-4; exact material must be stated |
| Evidence pattern | Predominantly preclinical, with very limited human data | Broad basic and translational literature for thymosin beta-4 |
| Catalog check | Full sequence, form, strength and vial count | Whether the item is full thymosin beta-4, a fragment or another defined material |
Recent reviews warn that BPC-157 has not completed the clinical development needed to support broad human claims. Thymosin beta-4 has a different research history, but findings for the endogenous 43-amino-acid peptide should not automatically be transferred to any product using the TB-500 label.
How to compare single-compound and blend listings
NOVABIO lists BPC-157, TB-500 / Thymosin Beta-4 and a BPC-157 plus TB-500 blend. For a blend, record both component names and look for a stated allocation. “10 mg blend” is a total catalog amount, not proof that each component contains 10 mg.
- Confirm whether the listing is single-compound or blended.
- Capture the exact long-form name and SKU.
- Check whether a TB-500 label defines the actual sequence.
- Separate total mass from per-component mass.
- Match every scientific claim to the material actually studied.
Use evidence boundaries, not marketing shortcuts
Repair and recovery keywords are common search language, but they can overstate what a paper establishes. Animal or cell findings are not proof of a clinical outcome. A good research record states the model, material, endpoint and limitation alongside the citation.
Browse the Repair & Structural Research collection, read the catalog naming guide, or contact NOVABIO for a product-identity question.
Frequently asked questions
Are BPC-157 and TB-500 the same peptide?
No. BPC-157 is described as a 15-amino-acid peptide. Thymosin beta-4 is a 43-amino-acid endogenous peptide, while TB-500 is a catalog term that requires an exact sequence or material description. Their literature, identity and analytical documentation should be evaluated separately.
Does a BPC-157 and TB-500 blend contain equal amounts?
Not necessarily. A total blend mass states the combined amount unless the specification gives a component-by-component allocation. Researchers should not divide the total automatically or infer a ratio from the product title. Record the declared composition and request clarification when the allocation is absent.
What evidence limitation matters most for BPC-157?
The main limitation is the gap between extensive preclinical reporting and sparse, low-quality human evidence. Recent reviews describe major translational and pharmaceutical-development gaps. That means cell or animal findings should be labeled as such and should not be rewritten as established human efficacy or safety.
Sources
- PubMed: BPC-157 translational barriers (accessed 2026-08-27)
- PubMed: BPC-157 systematic review (accessed 2026-08-27)
- PubMed: thymosin beta-4 functions (accessed 2026-08-27)
Research-use notice: This article explains catalog identity and published research. It is not medical advice, a treatment claim or a dosing guide. NOVABIO catalog products are presented for laboratory research and are not represented here as approved for human use.